商业价格与前列腺癌医保受益人的诊疗
该回顾性全国队列研究纳入2014至2019年新诊断前列腺癌的医保受益人,随访至2020年,以商业价格指数为主要暴露,以诊断后12个月前列腺癌相关医保支出为主要结局。结果显示,商业价格平均为医保价格的190%(范围102%-421%),人均支出为16,704美元;商业价格最低十分位邮编区域的患者标准化医保支出比最高十分位区域高1,485美元(95%CI 939至2,030)。作者结论认为,商业价格较高与标准化医保支出显著较低相关。
要点
- 商业价格平均为医保价格的190%(范围102%-421%)。
- 人均前列腺癌相关医保支出为16,704美元。
- 商业价格最低十分位区域的患者标准化医保支出比最高十分位区域高1,485美元(95%CI 939至2,030)。
核心结论
- 商业价格较高的地区,新诊断前列腺癌男性的标准化医保支出显著较低。
研究设计与样本
- 回顾性全国队列研究,纳入2014至2019年新诊断前列腺癌的医保受益人,随访至2020年。
- 主要暴露为商业价格指数,即泌尿外科医生常见服务的商业价格与医保价格之比。
- 主要结局为诊断后12个月内的前列腺癌相关医保支出。
主要发现
- 各邮编区域商业价格平均为医保价格的190%(范围102%-421%),人均支出为16,704美元。
- 商业价格最低十分位邮编区域的患者标准化医保支出比最高十分位区域高1,485美元(95%CI 939至2,030)。
- 在接受治疗的患者亚组中,商业价格最低十分位区域的患者标准化医保支出比最高十分位区域高1,461美元(95%CI 848至2,073)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the relationship between market dynamics, in the form of commercial prices paid to urologists, and utilization of services, as measured by Medicare spending, in men with newly diagnosed prostate cancer. METHODS: We performed a retrospective national cohort study of Medicare beneficiaries with newly diagnosed prostate cancer between 2014 and 2019, with follow-up through 2020. The primary exposure was the commercial price index (ie, the ratio of commercial prices to Medicare prices for a common set of services performed by urologists). The primary outcome was Medicare spending for prostate cancer in the 12-month period after diagnosis. RESULTS: Across zip codes, commercial prices were, on average, 190% of Medicare prices (range 102%-421%), with mean spending per beneficiary of $16,704. There was an inverse relationship between the price index and Medicare spending for men for prostate cancer. Specifically, standardized Medicare spending was $1485 (95%CI $939 to $2030) higher per beneficiary among those managed in zip codes at the bottom decile for commercial prices compared to the top decile. This effect was similar in the subgroup of men who underwent treatment, where standardized Medicare spending was $1461 (95%CI $848 to $2073) higher per beneficiary among those managed in zip codes in the bottom decile for commercial prices compared to the top decile. CONCLUSION AND RELEVANCE: Commercial prices for a set of frequently performed services are substantial higher than those paid by Medicare and vary widely across zip codes. Higher commercial prices were associated with significantly lower utilization, as measured by standardized Medicare spending, in men with newly diagnosed prostate cancer.
引用
- Maganty A, Kaufman SR, Oerline MK, et al. Commercial Prices and Care for Medicare Beneficiaries With Prostate Cancer. Urology. 2024. PMID: 39581508. doi:10.1016/j.urology.2024.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。